Skip to main content
NVDA+0.12%AAPL-0.11%GOOGL-0.39%MSFT+0.70%AMZN-0.59%TSM+1.56%SPCX+1.84%META-0.61%AVGO+0.82%TSLA-0.44%LLY-1.87%BRK-B-0.44%MU+3.59%SKHY+4.69%WMT-0.84%JPM-1.27%AMD+2.41%V-1.39%XOM+2.85%JNJ-1.58%ASMLa-1.08%MA-1.98%ABBV+0.18%CVX+2.82%INTC+2.33%0700.HK+0.94%COST-1.01%1398.HK-1.50%CSCO+1.82%KO-2.14%ORCL+1.43%UNH-0.25%PG-2.65%BAC-0.54%1816.HK+0.44%3988.HK-0.50%HD-2.83%CAT-1.95%0005.HK-1.04%PM-0.41%HSBA.L-1.40%AP2d-0.07%0857.HK-0.93%0939.HK+0.51%AMAT+1.85%GE-2.41%1288.HK-1.94%NVS-3.26%DELL+2.53%LRCX+1.10%EURAUD-1.63%EURCAD-1.41%AUDCHF+1.39%AUDUSD+1.26%EURNZD-1.24%CADCHF+1.17%EURJPY-1.04%USDCAD-1.03%NZDCHF+1.01%USDTHB+0.96%GBPAUD-0.92%NZDUSD+0.88%CHFJPY-0.84%USDPLN+0.72%GBPCAD-0.71%EURGBP-0.71%USDJPY-0.70%CHFNOK-0.67%PLNJPY-0.62%USDZAR+0.61%AUDJPY+0.61%GBPNZD-0.56%EURPLN+0.55%CHFSGD-0.48%GBPCHF+0.45%EURZAR+0.45%USDTRY+0.43%NZDSGD+0.42%GBPZAR+0.41%GBPTRY+0.41%AUDNZD+0.39%CHFSEK-0.39%EURUSD-0.37%AUDDKK+0.36%CADJPY+0.36%GBPJPY-0.36%GBPUSD+0.33%GBPHKD+0.32%USDMXN-0.31%GBPMXN-0.28%AUDSGD+0.28%EURCZK+0.28%EURNOK-0.28%EURCHF-0.24%USDCNH-0.24%AUDCAD+0.23%EURCNH-0.21%NOKJPY+0.19%NZDJPY+0.18%USDSEK+0.18%USDILS+0.16%USDDKK+0.16%NZDCAD-0.15%USDCHF+0.12%GBPSGD-0.11%USDNOK-0.11%EURHKD-0.10%EURSGD-0.09%AUDNOK+0.08%USDSGD+0.08%USDHKD-0.07%USDCOP-0.04%NZDMXN+0.02%SGDJPY+0.01%EURDKK-0.01%EURSEK+0.01%USOIL+3.79%UKOIL+3.23%XNGUSD-2.96%HG1+1.91%COCOA-0.90%XAGUSD-0.75%GAGUSD-0.73%C1-0.66%COFFEE-0.63%XAUUSD-0.53%GAUUSD-0.52%SUGAR+0.45%BTCUSD+0.28%ETHUSD+20.55%USDTUSD+0.02%XRPUSD+14.70%SOLUSD+14.32%TRXUSDT+0.50%ZECUSDT+1.35%DOGEUSD+19.00%XMRUSDT+0.96%LINKUSD+19.73%XLMUSD+0.76%BCHUSDT+4.29%UNIUSD+1.85%LTCUSD+13.73%SUIUSD+1.89%HBARUSDT-1.11%TONUSD+30.40%TAOUSDT+1.07%AAVEUSD+0.38%DOTUSDT+1.17%ICPUSDT+2.43%WLDUSDT-4.07%ONDOUSDT+0.47%ARBUSDT+0.19%JUPUSDT-0.30%ATOMUSDT+4.56%INJUSDT-0.87%STXUSDT-1.37%TIAUSDT-2.10%FETUSDT+1.19%PYTHUSDT+0.01%SEIUSDT+0.84%IMXUSDT+2.21%GRTUSDT+0.91%OPUSDT-0.11%WIFUSDT+1.37%IOTAUSDT-0.05%AXSUSDT+1.92%POLUSDT+1.50%FARTCOINUSDT+0.84%EOSUSDT-1.48%DYDXUSDT+2.02%GALAUSDT+1.41%ORDIUSDT+2.35%RONINUSDT+0.24%NOTUSDT+3.13%NVDA+0.12%AAPL-0.11%GOOGL-0.39%MSFT+0.70%AMZN-0.59%TSM+1.56%SPCX+1.84%META-0.61%AVGO+0.82%TSLA-0.44%LLY-1.87%BRK-B-0.44%MU+3.59%SKHY+4.69%WMT-0.84%JPM-1.27%AMD+2.41%V-1.39%XOM+2.85%JNJ-1.58%ASMLa-1.08%MA-1.98%ABBV+0.18%CVX+2.82%INTC+2.33%0700.HK+0.94%COST-1.01%1398.HK-1.50%CSCO+1.82%KO-2.14%ORCL+1.43%UNH-0.25%PG-2.65%BAC-0.54%1816.HK+0.44%3988.HK-0.50%HD-2.83%CAT-1.95%0005.HK-1.04%PM-0.41%HSBA.L-1.40%AP2d-0.07%0857.HK-0.93%0939.HK+0.51%AMAT+1.85%GE-2.41%1288.HK-1.94%NVS-3.26%DELL+2.53%LRCX+1.10%EURAUD-1.63%EURCAD-1.41%AUDCHF+1.39%AUDUSD+1.26%EURNZD-1.24%CADCHF+1.17%EURJPY-1.04%USDCAD-1.03%NZDCHF+1.01%USDTHB+0.96%GBPAUD-0.92%NZDUSD+0.88%CHFJPY-0.84%USDPLN+0.72%GBPCAD-0.71%EURGBP-0.71%USDJPY-0.70%CHFNOK-0.67%PLNJPY-0.62%USDZAR+0.61%AUDJPY+0.61%GBPNZD-0.56%EURPLN+0.55%CHFSGD-0.48%GBPCHF+0.45%EURZAR+0.45%USDTRY+0.43%NZDSGD+0.42%GBPZAR+0.41%GBPTRY+0.41%AUDNZD+0.39%CHFSEK-0.39%EURUSD-0.37%AUDDKK+0.36%CADJPY+0.36%GBPJPY-0.36%GBPUSD+0.33%GBPHKD+0.32%USDMXN-0.31%GBPMXN-0.28%AUDSGD+0.28%EURCZK+0.28%EURNOK-0.28%EURCHF-0.24%USDCNH-0.24%AUDCAD+0.23%EURCNH-0.21%NOKJPY+0.19%NZDJPY+0.18%USDSEK+0.18%USDILS+0.16%USDDKK+0.16%NZDCAD-0.15%USDCHF+0.12%GBPSGD-0.11%USDNOK-0.11%EURHKD-0.10%EURSGD-0.09%AUDNOK+0.08%USDSGD+0.08%USDHKD-0.07%USDCOP-0.04%NZDMXN+0.02%SGDJPY+0.01%EURDKK-0.01%EURSEK+0.01%USOIL+3.79%UKOIL+3.23%XNGUSD-2.96%HG1+1.91%COCOA-0.90%XAGUSD-0.75%GAGUSD-0.73%C1-0.66%COFFEE-0.63%XAUUSD-0.53%GAUUSD-0.52%SUGAR+0.45%BTCUSD+0.28%ETHUSD+20.55%USDTUSD+0.02%XRPUSD+14.70%SOLUSD+14.32%TRXUSDT+0.50%ZECUSDT+1.35%DOGEUSD+19.00%XMRUSDT+0.96%LINKUSD+19.73%XLMUSD+0.76%BCHUSDT+4.29%UNIUSD+1.85%LTCUSD+13.73%SUIUSD+1.89%HBARUSDT-1.11%TONUSD+30.40%TAOUSDT+1.07%AAVEUSD+0.38%DOTUSDT+1.17%ICPUSDT+2.43%WLDUSDT-4.07%ONDOUSDT+0.47%ARBUSDT+0.19%JUPUSDT-0.30%ATOMUSDT+4.56%INJUSDT-0.87%STXUSDT-1.37%TIAUSDT-2.10%FETUSDT+1.19%PYTHUSDT+0.01%SEIUSDT+0.84%IMXUSDT+2.21%GRTUSDT+0.91%OPUSDT-0.11%WIFUSDT+1.37%IOTAUSDT-0.05%AXSUSDT+1.92%POLUSDT+1.50%FARTCOINUSDT+0.84%EOSUSDT-1.48%DYDXUSDT+2.02%GALAUSDT+1.41%ORDIUSDT+2.35%RONINUSDT+0.24%NOTUSDT+3.13%
AB

ADMA Biologics, Inc. (ADMA)

NASDAQ • Healthcare

$10.95
-$0.06 (-0.5%)
Market open

Last close at October 22, 2026 at 20:00 UTC

Open$11.01
Previous Close$10.95
Day Range$10.8 - $11.11
Avg. Volume (3M)3M
Market Cap$2.3B
P/E Ratio15.2
52 Week Range
$7.21$20.46
Next EarningsIn 12 daysNov 4, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$124.3M100%
Gross Profitminus cost of goods$86.2M69%
Operating Incomeminus R&D and overhead$52.4M42%
Net Incomeminus taxes and the rest$37.8M30%

In plain terms: out of every $100 in revenue, ADMA Biologics, Inc. keeps $30 as net profit.

Fundamentals & Financials

Revenue (TTM)
$512.2M
Net Income (TTM)
$168.9M
EPS (TTM)
$0.72
ROA (TTM)
24.69%
Current Ratio
6.97

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+8.1%Q1 2026$0.2
-1.7%Q2 2026$0.19
-2.0%Q3 2026$0.16
Next

Nov 4

in 12 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -2.0%

ADMA Biologics missed consensus on both revenue and adjusted EPS in the second fiscal quarter of 2026, reported Aug. 5, even as revenue rose 2.0% to about $124.4 million. Gross margin held near 69% and operating margin around 42%, with operating income at about $52.4 million and net income rising 10.5% to about $37.8 million from about $34.2 million a year ago. Adjusted EPS was $0.16 versus the $0.16 estimate, a -2.0% miss, and operating cash flow came in at about $87.8 million. Consensus for the next period calls for EPS of $0.19 on revenue of $139.0 million.

Next report — what to expect

ADMA Biologics, Inc. (ADMA) is set to report earnings on November 4, 2026. Wall Street’s next-period consensus calls for EPS of $0.19 on revenue of $138.1 million. For trailing context, revenue was +2.0% year over year last quarter. ADMA has beaten EPS in 3 of 8 most recent quarters.

View full earnings history

About ADMA Biologics, Inc.

ADMA Biologics, Inc. (NASDAQ: ADMA) is a healthcare biotechnology company that develops, manufactures, and commercializes plasma-derived biologic therapies. Its business centers on immune globulin and hepatitis B products sold in the United States and abroad, and it generated $510.2 million of revenue in FY2025.

Name
ADMA Biologics, Inc.
CEO
Adam S. Grossman
Website
www.admabiologics.com
Industry
Healthcare
Year Founded
2004
Employees
644

Today's Snapshot

AI-generated

ADMA opened 0.6% below yesterday's close, in line with a weaker sector. ADMA is due to report earnings on 4 November.

Trading Volume

Below 10d avg (2.6M)

288.1K

vs S&P 500 Today

Underperforming Market

-2.75%

Updated: October 23, 2026 at 14:41 UTC

ADMA Headlines

Valuation Shifts In Major Healthcare Stocks

March 25, 2026

5 min read
View All News

Technical Indicators

4 Buy2 Neutral2 Sell
ADMA presents a constructive technical profile that supports a buy conclusion. The MACD is positive and ADX points to a strengthening trend, while the stock trades above its 20/50/100‑period averages, reflecting medium‑term upside alignment despite remaining below the 200‑day level. Momentum and RSI are neutral‑to‑positive and volatility is moderate, and OBV indicates buying interest even though the pivot is slightly overhead. Taken together, the weight of momentum, trend strength and medium‑term moving averages favors the bullish view. Technical takeaway: Buy — momentum and medium‑term averages support upside despite a 200‑day overhead.
All signals
  • EMA (5 indicators)$9.96 - $11.83
    Buy
  • RSI (14)56.55
    Neutral
  • Stochastic %K (14, 3, 3)68.45
    Neutral
  • MACD Level (12, 26)0.35
    Buy

Peers & Related Assets

ABUSArbutus Biopharma Corp
$4.21+0.7%
GRFSGrifols, S.A.
IVVDInvivyd, Inc.
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.